Open-label pilot study of ethosuximide as adjunctive therapy for relieving abdominal pain related to Irritable Bowel Syndrome.
Sahar M El-HaggarSahar K HegazySherief M Abd-ElsalamMostafa M BahaaPublished in: Journal of clinical pharmacy and therapeutics (2021)
Ethosuximide could be a promising adjunct to antispasmodics in the treatment of IBS patients. Trial registration identifier: NCT04217733.